Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...
Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...
The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...
The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...
Kenvue isn't growing as quickly as Eli Lilly or Zoetis, but it offers investors a strong starting point for dividend income.
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...